← ANALYST RATINGS · TIPRANKS
Alto Neuroscience, Inc. (ANRO): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $44.00, the highest $55.00, the lowest $37.00. The average is +100.5% from the last price of $21.94.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $27.00 → $24.50−9.3% | Hold | +11.7% | Reiterated | 06.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $26.00 → $23.50−9.6% | Hold | +7.1% | Reiterated | 06.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $25.00 → $23.50−6.0% | Hold | +7.1% | Reiterated | 06.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $26.00 → $23.50−9.6% | Hold | +7.1% | Reiterated | 06.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $26.00 → $23.50−9.6% | Hold | +7.1% | Reiterated | 06.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $25.00 → $23.50−6.0% | Hold | +7.1% | Reiterated | 06.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $26.00 → $25.00−3.8% | Hold | +13.9% | Reiterated | 04.10.26on TipRanks Oct 3 22:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $27.00 → $26.00−3.7% | Hold | +18.5% | Reiterated | 04.10.26on TipRanks Oct 3 22:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $27.00 → $26.00−3.7% | Hold | +18.5% | Reiterated | 02.10.26on TipRanks 20:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $27.00 → $26.00−3.7% | Hold | +18.5% | Reiterated | 02.10.26on TipRanks 20:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $26.00 → $25.00−3.8% | Hold | +13.9% | Reiterated | 02.10.26on TipRanks 20:05 | — | |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 02.10.26on TipRanks 15:25 | −2.8%next day −3.9% · 5 days −2.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $28.00 → $27.00−3.6% | Hold | +23.1% | Reiterated | 01.10.26on TipRanks 18:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $28.00 → $27.00−3.6% | Hold | +23.1% | Reiterated | 01.10.26on TipRanks 18:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $27.00 → $26.00−3.7% | Hold | +18.5% | Reiterated | 01.10.26on TipRanks 18:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $28.00 → $27.00−3.6% | Hold | +23.1% | Reiterated | 01.10.26on TipRanks 18:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $28.00 → $27.00−3.6% | Hold | +23.1% | Reiterated | 01.10.26on TipRanks 18:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $27.00 → $26.00−3.7% | Hold | +18.5% | Reiterated | 01.10.26on TipRanks 18:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $29.00 → $28.00−3.4% | Hold | +27.6% | Reiterated | 30.09.26on TipRanks 17:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $28.00 | Hold | +27.6% | Reiterated | 30.09.26on TipRanks 17:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $27.00 | Hold | +23.1% | Reiterated | 30.09.26on TipRanks 17:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $28.00 | Hold | +27.6% | Reiterated | 30.09.26on TipRanks 17:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $28.00 | Hold | +27.6% | Reiterated | 30.09.26on TipRanks 17:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $27.00 | Hold | +23.1% | Reiterated | 30.09.26on TipRanks 17:05 | — | |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $55.00 | Buy | +150.7% | Reiterated | 21.09.26on TipRanks 13:55 | −0.4%next day +0.5% · 5 days −11.9% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | — | Buy | — | Reiterated | 14.08.26on TipRanks 11:15 | −0.3%next day +5.0% · 5 days +8.0% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $35.00 → $40.00+14.3% | Buy | +82.3% | Reiterated | 13.08.26on TipRanks 10:45 | +10.0%next day −0.3% · 5 days +8.0% | ↗ |
| Thomas Shrader★★★★★★★★★★#2198 · hits 39% · avg +6.6% | BTIG | $28.00 → $37.00+32.1% | Buy | +68.6% | Assigned | 13.08.26on TipRanks 06:25 | +10.0%next day −0.3% · 5 days +8.0% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 13.08.26on TipRanks Aug 12 20:35 | +10.0%next day −0.3% · 5 days +8.0% | ↗ |
| Justin Walsh★★★★★★★★★★#640 · hits 39% · avg +20.6% | JonesTrading | $44.00 | Buy | +100.5% | Reiterated | 26.06.26on TipRanks 08:30 | +7.6%next day +2.2% · 5 days −6.1% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $38.00 → $36.00−5.3% | Buy | +64.1% | Reiterated | 18.05.26on TipRanks 07:40 | −5.1%next day −5.5% · 5 days −5.0% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $21.00 → $24.00+14.3% | Hold | +9.4% | Reiterated | 14.05.26on TipRanks 21:30 | −1.4%next day −5.1% · 5 days −8.5% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | — | Buy | — | Reiterated | 13.05.26on TipRanks May 14 03:45 | −7.8%next day +2.4% · 5 days −8.9% | ↗ |
| Keay Nakae★★★★★★★★★★#3914 · hits 40% · avg +3.0% | Chardan Capital | $30.00 | Buy | +36.7% | Reiterated | 21.04.26on TipRanks Apr 22 03:40 | −5.7%next day +5.1% · 5 days −5.5% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $33.00 | Buy | +50.4% | Reiterated | 02.04.26on TipRanks 08:05 | −7.5%next day +3.4% · 5 days +1.5% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $15.00 | Buy | −31.6% | Reiterated | 20.10.25on TipRanks Oct 21 02:10 | +79.9%next day −1.4% · 5 days +9.3% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Alto Neuroscience, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $44.00 at a price of $25.53 (+72.3%); now: $44.00 at $21.94 (+100.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 15 | 10 | 6 | 2 | 2 |
| Buy | 17 | 11 | 6 | 5 | 5 | 5 |
| Hold | 3 | 2 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About Alto Neuroscience, Inc.
- CEO: Amit Etkin
- Employees: 68
- 650 Castro Street, Mountain View, CA, 94041, US
- www.altoneuroscience.com
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Data from the stock’s TipRanks forecast page, read 18 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗